By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pierre Fabre 

Centre d'Immunologie Pierre FABRE
5, avenue Napolean III - BP 497
St. Julien en Genevois Cedex    74164  France
Phone: 33-4-50-35-35-55 Fax: 33-4-50-35-35-90




Merck & Co.  Cancer

Company News
Pierre Fabre And Addex Therapeutics (ADXN.SW) Sign Early-Stage Agreement In The Central Nervous System (CNS) Field 9/8/2015 10:33:04 AM
Pierre Fabre Release: Bladder Cancer Patients And Doctors Disappointed By Scottish Medicines Consortium's Negative Decision On Javlor (Vinflunine As Ditartrate) For The Treatment Of Adult Patients 7/13/2015 9:34:13 AM
Sigma-Tau Of ALFASIGMA Group Grants Pierre Fabre Exclusive License In 32 African Countries For Its Antimalarial Eurartesim 7/2/2015 10:30:10 AM
Biomax Informatics Collaborates With Pierre Fabre To Provide A Research Environment To Support Therapeutic Antibody Development 6/18/2015 10:17:30 AM
AbCheck s.r.o. And Pierre Fabre Enter Into Strategic Research Partnership 6/17/2015 9:54:04 AM
Pierre Fabre Release: A phase 2/3 Clinical Data Published In The NEJM Confirms Positive Safety-Efficacy Profile For First Pediatric Treatment For Infantile Hemangioma 2/20/2015 1:38:55 PM
Drugmaker Pierre Fabre To Slash 551 R&D Jobs By 2016 12/10/2014 6:10:24 AM
Pierre Fabre Obtains European Commission Marketing Authorization For Hemangiol®, The First And Only Drug Approved For The Treatment Of Proliferating Infantile Hemangioma 5/5/2014 9:05:15 AM
Pierre Fabre Selects Pierre Fabre Doccompliance To Manage Quality Documents Across Entire Organization 4/28/2014 9:56:19 AM
Pierre Fabre Obtains FDA Approval To Market Hemangeo™ For The Treatment Of Infantile Hemangioma 3/18/2014 6:57:31 AM